F-1/A: Evaxion Biotech Files Amendment for Resale of Ordinary Shares Represented by ADSs

Evaxion Biotech is filing an amendment to its registration statement for the resale of up to 19,453,796 ordinary shares represented by 1,945,379 American Depositary Shares (ADSs) by selling shareholders.

Summary

• Evaxion Biotech A/S has filed an amendment to its registration statement on Form F-1 with the SEC.
• The amendment pertains to the resale of up to 19,453,796 ordinary shares, represented by 1,945,379 American Depositary Shares (ADSs).
• These shares consist of (1) 9,726,898 ordinary shares represented by 972,689 ADSs and (2) 9,726,898 ordinary shares represented by 972,689 ADSs issuable upon exercise of warrants.
• The shares and warrants were previously sold to selling shareholders as part of a private placement that closed on December 21, 2023.
• The warrants have an exercise price of $0.707 per ordinary share (amended to 4.799 DKK as of June 12, 2024).
• The selling shareholders may sell or dispose of the ADSs in various ways and at varying prices.
• Evaxion Biotech will not receive any proceeds from the sale of ADSs by the selling shareholders, but may receive up to $6,876,917 upon exercise of the warrants.
• The company's ADSs are listed on The Nasdaq Capital Market under the symbol EVAX.
• On July 19, 2024, the closing sale price of the ADSs as reported on Nasdaq was $2.80 per ADS.
• The document includes legal opinions from Mazanti-Andersen Advokatpartnerselskab regarding the validity of the ordinary shares and Danish tax considerations.
• EY Godkendt Revisionspartnerselskab has provided consent for the incorporation by reference of their audit report on the company's 2023 financial statements.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While it doesn't represent new operational achievements, it facilitates potential future funding through warrant exercises. The risk of share price dilution is a concern, but the overall tone is balanced.

Positives

• The registration allows selling shareholders to offer their shares for resale, potentially increasing liquidity.
• Evaxion Biotech may receive up to $6,876,917 if all warrants are exercised, providing additional capital.
• The company has secured legal opinions from Mazanti-Andersen Advokatpartnerselskab, ensuring compliance with Danish law.
• EY Godkendt Revisionspartnerselskab has provided consent for the incorporation by reference of their audit report on the company's 2023 financial statements.

Negatives

• The company will not receive any proceeds from the sale of ADSs by the selling shareholders.
• The sale of a substantial amount of ordinary shares represented by ADSs in the public market could adversely affect the prevailing market price of the company's ordinary shares.

Risks

• The sale of a substantial amount of ordinary shares represented by ADSs, including resale of the ordinary shares represented by ADSs issuable upon the exercise of the warrants held by the selling shareholders in the public market could adversely affect the prevailing market price of our ordinary shares.
• The company is dependent upon successfully concluding partnerships to advance our product candidates to monetize our assets.
• The company will require substantial additional financing to achieve our goals, and a failure to obtain this capital on acceptable terms, or at all, could force us to delay, limit, scale back or cease our product development activities or any other or all operations.

Future Outlook

The company intends to use any proceeds from the exercise of warrants to advance its preclinical and clinical pipeline, and for continuing operating expenses and working capital.

Industry Context

This announcement is typical for biotech companies that have completed private placements and are registering the shares for resale, allowing early investors to liquidate their positions.

Comparison to Industry Standards

• The structure of the private placement with warrants is a common financing method in the biotech industry, especially for companies in the clinical stage.
• Comparable companies such as Genmab A/S and argenx SE also utilize public offerings and private placements to fund their research and development activities.
• The warrant exercise price and terms are within the typical range for similar biotech financings.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised and the selling shareholders sell their shares.
• The company's employees and partners may benefit from the advancement of the pipeline if the company receives proceeds from warrant exercises.

Next Steps

• The selling shareholders may proceed with the resale of the registered ADSs.
• The company may receive proceeds if the warrants are exercised.
• The company will continue to advance its preclinical and clinical pipeline.

Key Dates

Keywords

ADSs, ordinary shares, Evaxion Biotech, resale, warrants, private placement, registration statement, selling shareholders, Nasdaq, EVAX